Sightseeing Bio Signs Business Agreement With Einocle To Develop Precision Medical Systems
Oct 16, 2024
Gisaeng Biomaterials (CEO Park Hee-kyung, hereinafter Gisaeng Bio) announced that it will cooperate with Einocle (CEO Chung Hyun-woo and Choi Sung-kyun), a company specializing in single-cell multi-omics analysis, to develop a precision medical system.
On the 10th, the two companies signed a business agreement at the headquarters of Daejeon Sight Bio and decided to begin cooperation to build a next-generation medical system in earnest. At the signing ceremony, Park Hee-kyung, CEO of Sisa Bio, Kim Do-won, and Chung Hyun-woo and Choi Sung-kyun, CEO of Einocle, respectively attended and promised to strengthen cooperation.
Gaze Bio is a molecular diagnostic company based on genetic and epigenetic mutation information. In particular, it is expanding its business to various fields, including the recent cancer-related epigenome analysis panel business.
Through this agreement, the two companies will utilize automation devices and data analysis technology with low-cost, high-efficiency single-cell preprocessing technology from Inocle. In addition, it plans to seek cooperation measures for the development of precision medical systems by incorporating target-selective material technology of Sisa Bio. In addition, it plans to promote sharing of technology and know-how, joint use of cooperative networks, and joint commercialization.
Single-cell technology is known as an innovative approach that can analyze various molecular information at the individual cell level. Above all, it plays an important role in deeply understanding the complexity and heterogeneity of disease-linked cells and interaction between cells. The technology is widely used in various fields such as cancer research, developmental biology, immunology, and molecular diagnosis. In recent years, it has greatly contributed to the development of precision medical care.
Einocle was co-founded in 2020 by CEO Chung Hyeon-woo from the Max Planck Institute of Molecular Biomedical Sciences in Germany and CEO Choi Sung-kyun from the Department of Mechanical Engineering at Korea University. Recently, it has focused on developing a precise diagnosis system for several rare intractable diseases such as COVID-19 infections and lung cancer.
Park Hee-kyung, CEO of Sinshi Bio, said "We expect this agreement to have a positive impact on the research and development of both companies.""We hope that through cooperation, Gisaeng Bio's technology will be recognized as a target selection material, which is a key factor in expanding the single cell analysis base.""
Through this agreement, the two companies plan to work together to develop and build a precision medical system based on multi-omics, and based on this, maximize application potential in the medical field. It is expected that the cooperation between the two companies will bring about results in the future.
On the 10th, the two companies signed a business agreement at the headquarters of Daejeon Sight Bio and decided to begin cooperation to build a next-generation medical system in earnest. At the signing ceremony, Park Hee-kyung, CEO of Sisa Bio, Kim Do-won, and Chung Hyun-woo and Choi Sung-kyun, CEO of Einocle, respectively attended and promised to strengthen cooperation.
Gaze Bio is a molecular diagnostic company based on genetic and epigenetic mutation information. In particular, it is expanding its business to various fields, including the recent cancer-related epigenome analysis panel business.
Through this agreement, the two companies will utilize automation devices and data analysis technology with low-cost, high-efficiency single-cell preprocessing technology from Inocle. In addition, it plans to seek cooperation measures for the development of precision medical systems by incorporating target-selective material technology of Sisa Bio. In addition, it plans to promote sharing of technology and know-how, joint use of cooperative networks, and joint commercialization.
Single-cell technology is known as an innovative approach that can analyze various molecular information at the individual cell level. Above all, it plays an important role in deeply understanding the complexity and heterogeneity of disease-linked cells and interaction between cells. The technology is widely used in various fields such as cancer research, developmental biology, immunology, and molecular diagnosis. In recent years, it has greatly contributed to the development of precision medical care.
Einocle was co-founded in 2020 by CEO Chung Hyeon-woo from the Max Planck Institute of Molecular Biomedical Sciences in Germany and CEO Choi Sung-kyun from the Department of Mechanical Engineering at Korea University. Recently, it has focused on developing a precise diagnosis system for several rare intractable diseases such as COVID-19 infections and lung cancer.
Park Hee-kyung, CEO of Sinshi Bio, said "We expect this agreement to have a positive impact on the research and development of both companies.""We hope that through cooperation, Gisaeng Bio's technology will be recognized as a target selection material, which is a key factor in expanding the single cell analysis base.""
Through this agreement, the two companies plan to work together to develop and build a precision medical system based on multi-omics, and based on this, maximize application potential in the medical field. It is expected that the cooperation between the two companies will bring about results in the future.
|
bellho@sportschosun.com
